Acadian Asset Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $131M | Buy |
2,736,697
+2,286,233
| +508% | +$98.2M | 0.16% | 128 |
|
|
2026
Q1 | $16.5M | Buy |
450,464
+360,735
| +402% | +$17.1M | 0.02% | 415 |
|
|
2025
Q4 | $4.56M | Sell |
89,729
-129,455
| -59% | -$6.62M | 0.01% | 678 |
|
|
2025
Q3 | $12.2M | Sell |
219,184
-116,403
| -35% | -$6.81M | 0.02% | 432 |
|
|
2025
Q2 | $23.1M | Sell |
335,587
-709,071
| -68% | -$48.2M | 0.05% | 288 |
|
|
2025
Q1 | $72.5M | Buy |
1,044,658
+1,038,137
| +15,920% | +$85.7M | 0.21% | 105 |
|
|
2024
Q4 | $559K | Sell |
6,521
-143,139
| -96% | -$15.5M | ﹤0.01% | 1051 |
|
|
2024
Q3 | $17.8M | Sell |
149,660
-200,294
| -57% | -$26.7M | 0.06% | 248 |
|
|
2024
Q2 | $49.9M | Sell |
349,954
-894,174
| -72% | -$118M | 0.15% | 140 |
|
|
2024
Q1 | $160M | Buy |
1,244,128
+1,155,313
| +1,301% | +$138M | 0.56% | 43 |
|
|
2023
Q4 | $9.18M | Buy |
88,815
+82,963
| +1,418% | +$8.2M | 0.04% | 304 |
|
|
2023
Q3 | $531K | Sell |
5,852
-11,536
| -66% | -$1.02M | ﹤0.01% | 989 |
|
|
2023
Q2 | $1.41M | Buy |
17,388
+8,298
| +91% | +$678K | 0.01% | 796 |
|
|
2023
Q1 | $723K | Sell |
9,090
-8,506
| -48% | -$603K | ﹤0.01% | 960 |
|
|
2022
Q4 | $1.19M | Sell |
17,596
-2,110
| -11% | -$124K | 0.01% | 805 |
|
|
2022
Q3 | $981K | Hold |
19,706
| – | – | 0.01% | 807 |
|
|
2022
Q2 | $1.1M | Hold |
19,706
| – | – | 0.01% | 791 |
|
|
2022
Q1 | $1.09M | Sell |
19,706
-3,538
| -15% | -$182K | ﹤0.01% | 810 |
|
|
2021
Q4 | $1.3M | Sell |
23,244
-324
| -1% | -$17.6K | ﹤0.01% | 768 |
|
|
2021
Q3 | $1.13M | Buy |
+23,568
| New | +$1.14M | ﹤0.01% | 808 |
|
|
2021
Q1 | – | Sell |
-35,118
| Closed | -$1.23M | – | 2240 |
|
|
2020
Q4 | $1.23M | Sell |
35,118
-18
| -0.1% | -$622 | ﹤0.01% | 917 |
|
|
2020
Q3 | $1.22M | Hold |
35,136
| – | – | 0.01% | 833 |
|
|
2020
Q2 | $1.15M | Buy |
35,136
+2,694
| +8% | +$86K | 0.01% | 911 |
|
|
2020
Q1 | $977K | Buy |
+32,442
| New | +$966K | 0.01% | 799 |
|
|
2019
Q4 | – | Sell |
-1,866
| Closed | -$48K | – | 2016 |
|
|
2019
Q3 | $48K | Buy |
+1,866
| New | +$47.2K | ﹤0.01% | 1621 |
|
|
2017
Q4 | – | Sell |
-2,546
| Closed | -$61K | – | 1650 |
|
|
2017
Q3 | $61K | Sell |
2,546
-496
| -16% | -$11.2K | ﹤0.01% | 1083 |
|
|
2017
Q2 | $65K | Buy |
+3,042
| New | +$61.4K | ﹤0.01% | 1091 |
|
|
2016
Q1 | – | Sell |
-15,512
| Closed | -$450K | – | 1444 |
|
|
2015
Q4 | $450K | Sell |
15,512
-292,332
| -95% | -$8.09M | ﹤0.01% | 826 |
|
|
2015
Q3 | $8.35M | Buy |
307,844
+301,112
| +4,473% | +$8.53M | 0.05% | 313 |
|
|
2015
Q2 | $185K | Buy |
6,732
+3,278
| +95% | +$92.1K | ﹤0.01% | 943 |
|
|
2015
Q1 | $92K | Buy |
3,454
+496
| +17% | +$11.4K | ﹤0.01% | 1033 |
|
|
2014
Q4 | $63K | Buy |
+2,958
| New | +$66.1K | ﹤0.01% | 1041 |
|
Other funds holding NVO
F
Acadian Asset Management's NVO Position: Q2 2026 in Review
Acadian Asset Management increased its Novo Nordisk (NVO) stake by 508% in Q2 2026, buying an estimated $98.2M and bringing the position to 2,736,697 shares worth $131M. The position accounts for 0.16% of the portfolio, ranked #128.
Acadian Asset Management first reported a position in NVO in Q4 2014 and has held it in 32 quarters since. The position peaked at $160M in Q1 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Acadian Asset Management held 2,736,697 shares of Novo Nordisk worth $131M as of Q2 2026.
- Acadian Asset Management bought 2,286,233 Novo Nordisk shares in Q2 2026, an estimated $98.2M.
- Novo Nordisk made up 0.16% of Acadian Asset Management's portfolio in Q2 2026, its #128 holding.
- Acadian Asset Management first reported a position in Novo Nordisk in Q4 2014 and has held it in 32 quarters since.
- Acadian Asset Management's Novo Nordisk position peaked at $160M in Q1 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.